Literature DB >> 20308723

High ghrelin and obestatin levels and low risk of developing fatty liver.

Ylse Gutierrez-Grobe1, Israel Villalobos-Blasquez, Karla Sánchez-Lara, Antonio R Villa, Guadalupe Ponciano-Rodríguez, Martha H Ramos, Norberto C Chavez-Tapia, Misael Uribe, Nahum Méndez-Sánchez.   

Abstract

AIM: Obesity and insulin resistance are associated with nonalcoholic fatty liver disease (NAFLD). It was recently reported that the ratio between levels of ghrelin and obestatin is also associated with obesity and insulin resistance. We investigated the association between the ghrelin/obestatin ratio and NAFLD.
METHODS: This cross-sectional study included 98 subjects (51 NAFLD patients and 47 controls). Anthropometric, metabolic and biochemical variables were measured and serum concentrations of ghrelin and obestatin were determined. Logistic regression analyses (univariate and multivariate) were conducted to determine whether NAFLD was associated with ghrelin and obestatin levels and the ghrelin/obestatin ratio.
RESULTS: We studied 51 NAFLD cases and 47 controls. Men comprised 82% of cases and 61% of controls. The mean ages of the groups differed significantly. Body mass index (P < 0.001), waist circumference (P < 0.001) and WHR (P < 0.001) were significantly greater in the NAFLD group than in the control group. The NAFLD group had higher mean fasting glucose level (P = 0.001), HOMA-IR index (P < 0.001) and triglyceride level (P < 0.001) than the controls. Ghrelin and obestatin concentrations were classed according to tertiles. Multivariate analysis revealed a negative correlation between ghrelin and obestatin levels and an overweight status, obesity and metabolic syndrome. Ghrelin and obestatin were evaluated in multivariate logistic regression analysis, they had a protective effect against hepatic steatosis after controlling for potential confounders.
CONCLUSION: Serum ghrelin and obestatin concentrations are correlated with a low risk of developing NAFLD. However, ghrelin/obestatin ratio was not correlated with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308723

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  13 in total

Review 1.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

2.  Ghrelin: a new treatment for non-alcoholic fatty liver disease?

Authors:  Patric J D Delhanty; Aart J van der Lely
Journal:  Endocrine       Date:  2012-09-20       Impact factor: 3.633

3.  Obestatin and Rosiglitazone Differentially Modulate Lipid Metabolism Through Peroxisome Proliferator-activated Receptor-γ (PPARγ) in Pre-adipose and Mature 3T3-L1 Cells.

Authors:  Mallikarjuna B G; Uma V Manjappara
Journal:  Cell Biochem Biophys       Date:  2021-01-11       Impact factor: 2.194

4.  Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function.

Authors:  Paweł A Kołodziejski; Ewa Pruszyńska-Oszmałek; Mathias Z Strowski; Krzysztof W Nowak
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

Review 5.  Biological effects of obestatin.

Authors:  Jiang-Bo Li; Akihiro Asakawa; Kaichun Cheng; Yingxiao Li; Huhe Chaolu; Minglun Tsai; Akio Inui
Journal:  Endocrine       Date:  2011-03-20       Impact factor: 3.633

6.  Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels.

Authors:  Celal Ulasoglu; Banu Isbilen; Levent Doganay; Filiz Ozen; Safak Kiziltas; Ilyas Tuncer
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

7.  Nonalcoholic fatty liver disease and type 2 diabetes in obese children.

Authors:  Lior Hecht; Ram Weiss
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

8.  Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease.

Authors:  Rohini Mehta; Aybike Birerdinc; Lei Wang; Zahra Younoszai; Amir Moazzez; Hazem Elariny; Zachary Goodman; Vikas Chandhoke; Ancha Baranova; Zobair M Younossi
Journal:  BMC Gastroenterol       Date:  2014-04-09       Impact factor: 3.067

9.  Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients.

Authors:  Galyna Mykhalchyshyn; Nazarii Kobyliak; Petro Bodnar
Journal:  J Diabetes Metab Disord       Date:  2015-05-19

Review 10.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.